SCHEDULE 13G: Biotechnology Value Fund Group Discloses 7.2% Passive Stake in Monte Rosa Therapeutics

A group of investment entities led by Mark N. Lampert, including Biotechnology Value Fund L.P. and its affiliates, has disclosed a collective beneficial ownership of 7.2% in Monte Rosa Therapeutics, Inc. through a Schedule 13G filing.

Summary

• The filing is a Schedule 13G, indicating passive beneficial ownership of shares in Monte Rosa Therapeutics, Inc.
• The reporting group consists of multiple entities, including Biotechnology Value Fund L.P., BVF I GP LLC, Biotechnology Value Fund II LP, BVF II GP LLC, Biotechnology Value Trading Fund OS LP, BVF Partners OS Ltd., BVF GP HOLDINGS LLC, BVF PARTNERS L P/IL, BVF INC/IL, and Mark N. Lampert.
• As of January 31, 2025, Mark N. Lampert, BVF Partners L.P./IL, and BVF Inc./IL each beneficially own 4,393,210 shares of Monte Rosa Therapeutics' Common Stock.
• This aggregate ownership represents approximately 7.2% of the outstanding shares of Monte Rosa Therapeutics, Inc.
• The percentage is calculated based on 61,436,740 shares outstanding as of November 4, 2024, as reported in the Issuer's Form 10-Q.
• The shares were not acquired for the purpose of changing or influencing the control of the issuer, other than activities solely in connection with a nomination under Rule 14a-11.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership, which is neutral in sentiment. It does not contain positive or negative operational or financial news about the issuer.

Risks

• The reporting persons certify that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer, other than activities solely in connection with a nomination under Rule 14a-11. Any deviation from this passive intent could be a risk for the issuer's management.

Future Outlook

N/A

Industry Context

This filing indicates a significant passive investment by a specialized biotechnology fund group in Monte Rosa Therapeutics, a company operating within the biotechnology sector. Such disclosures are common for institutional investors taking substantial, non-controlling stakes in public companies, particularly in growth-oriented sectors like biotech.

Related Party Transactions

• The filing details the hierarchical relationships and shared voting/dispositive powers among the various entities within the Biotechnology Value Fund group, including Mark N. Lampert, who is an authorized signatory for all reporting entities.

Stakeholder Impact

• Shareholders: The disclosure of a significant 7.2% stake by a prominent investment group may be viewed positively by other investors, signaling confidence in Monte Rosa Therapeutics. It also identifies a major shareholder group.

Key Dates

Keywords

Monte Rosa Therapeutics, Biotechnology Value Fund, Schedule 13G, Beneficial Ownership, Passive Investment, Biotechnology, MRTX, Institutional Investor